The Safe-BioPharma standards are used to mitigate legal, regulatory and other business risk associated with business-to-business and business-to-regulator electronic transactions.
Safe-BioPharma CEO Mollie Shields-Uehling said that applying signatures “to mission-critical documents establishes a robust and defensible record of invention for R&D companies needing to protect and defend their IP."
Trevor Heritage, president of Symyx’ software unit, said that joining Safe-BioPharma brings the firm into line with major pharmaceutical companies such as Pfizer, Eli Lilly and AstraZeneca.